Provided by Tiger Fintech (Singapore) Pte. Ltd.

Perspective Therapeutics

2.58
+0.18007.50%
Post-market: 2.580.00000.00%16:04 EDT
Volume:902.82K
Turnover:2.33M
Market Cap:191.51M
PE:-2.12
High:2.69
Open:2.40
Low:2.40
Close:2.40
Loading ...

Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 in Combination with Nivolumab in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma

GlobeNewswire
·
17 Mar

Analysts Offer Insights on Healthcare Companies: Zai Lab (ZLAB), Perspective Therapeutics (CATX) and Edesa Biotech (EDSA)

TIPRANKS
·
13 Mar

HC Wainwright Initiates Coverage on Perspective Therapeutics With Buy Rating, $10 Price Target

MT Newswires Live
·
13 Mar

Perspective Therapeutics Initiated at Buy by HC Wainwright & Co.

Dow Jones
·
13 Mar

Perspective Therapeutics initiated with a Buy at H.C. Wainwright

TIPRANKS
·
13 Mar

Perspective Therapeutics, Inc. : H.c. Wainwright Initiates Coverage With Buy Rating and Target Price $10

THOMSON REUTERS
·
13 Mar

Brookline Initiates Perspective Therapeutics at Buy With $11 Price Target

MT Newswires Live
·
10 Mar

Perspective Therapeutics Initiated at Sector Outperform by Scotiabank

Dow Jones
·
08 Mar

Promising Outlook for Perspective Therapeutics: Buy Rating Backed by Positive Trial Data and Market Positioning

TIPRANKS
·
07 Mar

LNTH: 2025 Guidance Provided

Zacks Small Cap Research
·
28 Feb

Perspective Therapeutics to Provide Business Highlights and Report Full Year 2024 Financial Results

GlobeNewswire
·
21 Feb

Perspective Therapeutics to Participate in Upcoming February Investor Conferences

GlobeNewswire
·
05 Feb

Analysts Offer Insights on Healthcare Companies: Perspective Therapeutics (CATX) and iCAD (ICAD)

TIPRANKS
·
27 Jan

Analysts Offer Insights on Healthcare Companies: Perspective Therapeutics (CATX), Axsome Therapeutics (AXSM) and HCA Healthcare (HCA)

TIPRANKS
·
26 Jan

Promising Clinical Developments and Strong Financial Position Reinforce ‘Buy’ Rating for Perspective Therapeutics

TIPRANKS
·
25 Jan

Perspective Therapeutics Touts Encouraging Updated Data From Gastrointestinal Cancer Trial, Stock Soars

Benzinga
·
25 Jan

Perspective Therapeutics Says Updated Interim Findings From Phase 1/2a Study Support Further Dose-Finding Research

MT Newswires Live
·
24 Jan

Perspective continues to pursue dose escalation of 212PbVMT-alpha-NET

TIPRANKS
·
24 Jan

Perspective Therapeutics Continues to Pursue Dose Escalation of [212PB]Vmt-Α-Net in Its Ongoing Phase 1/2a Clinical Trial Based on Updated Interim Data Presented at the 2025 Asco Gastrointestinal Cancers Symposium

THOMSON REUTERS
·
24 Jan

Perspective Therapeutics Continues to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Updated Interim Data Presented at the 2025 ASCO Gastrointestinal Cancers Symposium

GlobeNewswire
·
24 Jan